Histological improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether one‐food elimination diet changes histological improvement at 6 weeks (dichotomous) compared with six‐food elimination diet (very low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · active EoE pediatric patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events compared with six‐food elimination diet (very low certainty).
1 finding from 1 review
Body‐mass index (BMI) · children aged 6‐12 years
1 finding from 1 review
Body‐mass index z score (zBMI) · children aged 6‐12 years
1 finding from 1 review
Mean GI symptom scores (IBDQ‐B) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
1 finding from 1 review
Acute and late GI toxicity (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diarrhoea (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Diet interventions showed no clear difference in diarrhoea (grade 2+) compared with usual on‐treatment diet (low certainty).
1 finding from 1 review
QoL · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Diet interventions showed no clear difference in QOL scores (IBDQ) (higher scores better) compared with usual on‐treatment diet (low certainty).
3 findings from 1 review
MD 4.6
1 study · 50 participants
Low
no estimate extracted
1 study · 119 participants
GRADE not reported
MD 2.4
1 study · 76 participants
Low
Diarrhoea (grade 1+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Diet interventions showed no clear difference in diarrhoea (grade 1+) compared with usual on‐treatment diet (low certainty).
1 finding from 1 review
Mean GI symptom scores (Vaizey scale) (higher scores better) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Diet interventions showed no clear difference in mean GI symptom scores (Vaizey scale) (higher scores better) compared with usual on‐treatment diet (low certainty).
1 finding from 1 review
Diarrhoea · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Seizure freedom · children (aged 1 to 18 years) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes seizure freedom (100% reduction in seizure frequency) compared with usual care (very low certainty).
1 finding from 1 review
Cognition and behaviour · adults (aged 16 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults (aged 16 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment withdrawal · adults (aged 16 years and over) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes treatment withdrawal compared with usual care (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · children (aged 1 to 18 years) with drug‐resistant epilepsy
1 finding from 1 review
Adverse effects · children (aged 1 to 18 years) with drug‐resistant epilepsy
1 finding from 1 review